PMID- 7967757
OWN - NLM
STAT- MEDLINE
DCOM- 19941208
LR  - 20190516
IS  - 0025-6196 (Print)
IS  - 0025-6196 (Linking)
VI  - 69
IP  - 11
DP  - 1994 Nov
TI  - Efficacy of fluorescence in situ hybridization for detecting PML/RARA gene fusion 
      in treated and untreated acute promyelocytic leukemia.
PG  - 1047-53
AB  - OBJECTIVE: To test the efficacy of fluorescence in situ hybridization (FISH) for 
      detection of fusion of the promyelocytic leukemia (PML) and retinoic acid 
      receptor alpha (RARA) genes in patients with treated or untreated acute 
      promyelocytic leukemia (APL). DESIGN: We conducted a retrospective blind study on 
      a series of stored bone marrow specimens from normal subjects and patients with 
      APL. MATERIAL AND METHODS: Conventional cytogenetic and FISH analyses were done 
      on interphase and metaphase cells in specimens from 31 normal subjects and 19 
      patients with untreated or treated APL. RESULTS: From 25 of the normal specimens, 
      we calculated a normal cutoff of 10% for interphase cells and 0% for metaphase 
      cells. With use of these criteria, the other six specimens from normal subjects 
      showed normal findings, and each of the seven specimens from patients with 
      untreated APL was abnormal by FISH analysis. The specimens from four patients in 
      clinical relapse or with residual APL were abnormal. Of the eight specimens from 
      patients in clinical remission, three were abnormal; two of these patients had a 
      relapse within 8 months, and the other patient had received 1 month of 
      chemotherapy and was entering remission. Of the other five patients in remission, 
      four had normal FISH results and have now been in remission for 2.5 to 10 years. 
      The other patient in remission with normal FISH results had a relapse within 6 
      months. PML/RARA fusion was detectable in three patients with hypogranular APL 
      and in three with a cytogenetic variant of the t(15;17). CONCLUSION: The results 
      of this study suggest that FISH with PML and RARA probes can be used to diagnose 
      APL and may be useful for monitoring treated patients.
FAU - Schad, C R
AU  - Schad CR
AD  - Division of Laboratory Genetics, Mayo Clinic Rochester, MN 55905.
FAU - Hanson, C A
AU  - Hanson CA
FAU - Paietta, E
AU  - Paietta E
FAU - Casper, J
AU  - Casper J
FAU - Jalal, S M
AU  - Jalal SM
FAU - Dewald, G W
AU  - Dewald GW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 0 (Antineoplastic Agents)
RN  - 0 (RARA protein, human)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoic Acid Receptor alpha)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - *Cloning, Molecular
MH  - Genes
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Interphase/genetics
MH  - Leukemia, Promyelocytic, Acute/diagnosis/drug therapy/*genetics
MH  - Metaphase/genetics
MH  - Receptors, Retinoic Acid/genetics
MH  - Retinoic Acid Receptor alpha
MH  - Retrospective Studies
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
AID - S0025-6196(12)61371-8 [pii]
AID - 10.1016/s0025-6196(12)61371-8 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 1994 Nov;69(11):1047-53. doi: 10.1016/s0025-6196(12)61371-8.